Immunomodulatory treatment of HBsAg positive chronic hepatitis with specific substance Maruyama (SSM).
D000293:Adolescent; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001219:Aspartate Aminotransferases / Q000097:blood; D001688:Biological Products / Q000627:therapeutic use*; D005260:Female; D006509:Hepatitis B / Q000201:enzymology / Q000276:immunology / Q000628:therapy*; D006514:Hepatitis B Surface Antigens / Q000032:analysis*; D006801:Humans; D008055:Lipids; D008297:Male; D008351:Mannans; D008875:Middle Aged
D000970:Antineoplastic Agents; D001688:Biological Products; D006514:Hepatitis B Surface Antigens; D008055:Lipids; D008351:Mannans; C031208:specific substance maruyama; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase